|Bid||6.61 x 1000|
|Ask||6.68 x 800|
|Day's Range||6.48 - 6.84|
|52 Week Range||2.47 - 9.74|
|Beta (5Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LONDON, UK / ACCESSWIRE / September 2, 2020 / We are reinitiating on Kazia Therapeutics (NASDAQ:KZIA), which is entering late-stage trials for its lead product, paxalisib, for glioblastoma multiforme (GBM).
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Kazia Therapeutics...
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of malignant glioma, which includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.